caa a22 4500 445330864 CHVBK 20180317142736.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s10689-011-9435-0 doi (NATIONALLICENCE)springer-10.1007/s10689-011-9435-0 Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer [Elektronische Daten] [B. Kiely, M. Friedlander, R. Milne, L. Stanhope, P. Russell, M. Jenkins, P. Weideman, S. McLachlan, P. Grant, J. Hopper, K. Phillips] The aim of this study was to describe the type of risk-reducing gynaecologic surgery (RRGS) and the extent of pathological evaluation being undertaken for Australasian women at high familial risk of pelvic serous cancer. Surgical and pathology reports were reviewed for women with BRCA1/BRCA2 mutations, or a family history of breast and ovarian cancer, who underwent RRGS between 1998 and 2008. "Adequate” surgery was defined as complete removal of all ovarian and extra-uterine fallopian tube tissue. "Adequate” pathology was defined as paraffin embedding of all removed ovarian and tubal tissue. Predictors of adequacy were assessed using logistic regression. There were 201 women, including 173 mutation carriers, who underwent RRGS. Of these, 91% had adequate surgery and 23% had adequate pathology. Independent predictors of adequate surgery were surgeon type (OR=20; 95% CI 2-167; P=0.005 for gynaecologic oncologists versus general gynaecologists), more recent surgery (OR=1.33/year; 95% CI 1.07-1.67; P=0.012) and younger patient age (OR=0.93/year of age; 95% CI 0.87-0.99; P=0.028). Independent predictors of adequate pathology were more recent surgery (OR=1.26/year; 95% CI 1.06-1.49; P=0.008) and surgeon type (OR=3.1; 95% CI 1.4-6.7; P=0.004 for gynaecologic oncologists versus general gynaecologists). Four serous ovarian cancers and one endometrioid endometrial cancer were detected during surgery or pathological examination. In conclusion Australasian women attending a specialist gynaecologic oncologist for RRGS are most likely to have adequate surgery and pathological examination. Additional education of clinicians and consumers is needed to ensure optimal surgery and pathology in these women. The Author(s), 2011 BRCA1/BRCA2 mutations nationallicence Cancer prevention nationallicence Ovarian cancer nationallicence Prophylactic salpingo-oophorectomy nationallicence Risk-reducing surgery nationallicence RRGS : Risk-reducing gynaecologic surgery nationallicence RRSO : Risk-reducing salpingo-oophorectomy nationallicence kConFab : Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer nationallicence RANZCOG : Royal Australian and New Zealand College of Obstetricians and Gynaecologists nationallicence DCIS : Ductal carcinoma in situ nationallicence f/up : Follow-up nationallicence FDR : First degree relative nationallicence BC : Breast cancer nationallicence OC : Ovarian cancer nationallicence BO : Bilateral oophorectomy nationallicence TAH-BSO : Total abdominal hysterectomy and bilateral salpingo-oophorectomy nationallicence N/A : Not available nationallicence R : Right nationallicence L : Left nationallicence Kiely B. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut Friedlander M. Department of Medical Oncology, Prince of Wales Hospital, Sydney, NSW, Australia aut Milne R. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut Stanhope L. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut Russell P. Departments of Anatomical Pathology and Medicine Royal Prince Alfred Hospital, The University of Sydney, Sydney, NSW, Australia aut Jenkins M. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut Weideman P. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut McLachlan S. Department of Medical Oncology, St Vincent's Hospital, Fitzroy, VIC, Australia aut Grant P. Gynaecological Oncology Unit, Mercy Hospital For Women, Heidelberg, VIC, Australia aut Hopper J. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut Phillips K. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut Familial Cancer Springer Netherlands 10/3(2011-09-01), 505-514 1389-9600 10:3<505 2011 10 10689 https://doi.org/10.1007/s10689-011-9435-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10689-011-9435-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kiely B. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- Friedlander M. Department of Medical Oncology, Prince of Wales Hospital, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Milne R. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- Stanhope L. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- Russell P. Departments of Anatomical Pathology and Medicine Royal Prince Alfred Hospital, The University of Sydney, Sydney, NSW, Australia aut NATIONALLICENCE 700 1- Jenkins M. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- Weideman P. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- McLachlan S. Department of Medical Oncology, St Vincent's Hospital, Fitzroy, VIC, Australia aut NATIONALLICENCE 700 1- Grant P. Gynaecological Oncology Unit, Mercy Hospital For Women, Heidelberg, VIC, Australia aut NATIONALLICENCE 700 1- Hopper J. Centre for Molecular, Environmental, Genetic & Analytic Epidemiology, School of Population Health, The University of Melbourne, Melbourne, VIC, Australia aut NATIONALLICENCE 700 1- Phillips K. Division of Cancer Medicine, Peter MacCallum Cancer Centre, A'Beckett St, Locked Bag 1, 8006, Melbourne, VIC, Australia aut NATIONALLICENCE 773 0- Familial Cancer Springer Netherlands 10/3(2011-09-01), 505-514 1389-9600 10:3<505 2011 10 10689 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer